Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin.
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2015
At a glance
- Drugs Tanespimycin; Trastuzumab
- Indications Advanced breast cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb; Kosan Biosciences
- 11 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Nov 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 11 Nov 2009 Planned number of patients changed from 50 to 57 as reported by ClinicalTrials.gov.